Optimization of Treatment Strategy for Unresectable cN3 Esophageal Squamous Cell Carcinoma
Status:
Recruiting
Trial end date:
2026-11-01
Target enrollment:
Participant gender:
Summary
This study aims to investigate a comprehensive therapeutic approach for patients with
unresectable esophageal squamous cell carcinoma, clinically staged as Tany, N3, M0, and who
are not candidate for concurrent chemoradiotherapy combined with immunotherapy. The approach
entails combining chemotherapy with immune therapy, followed by synchronized radiotherapy
during the immune maintenance phase. The primary goal is to mitigate treatment-related side
effects and enhance the overall prognosis through the integration of these treatment
modalities.